To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:231 Issue:1 Number:1 ISSN#:2564-2537
ACE Report #14583
Ace Report Cover Osteoarthritis

Zoledronic Acid for Nonmalignant Painful Bone Marrow Lesions

How to Cite

OrthoEvidence. Zoledronic Acid for Nonmalignant Painful Bone Marrow Lesions. ACE Report. 2022;231(1):1. Available from:

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Efficacy of Zoledronic Acid in the Treatment of Nonmalignant Painful Bone Marrow Lesions: A Triple-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial (ZoMARS)

J Bone Miner Res. 2022 Mar;37(3): 420-427.

Contributing Authors:
L Seefried F Genest J Baumann A Heidemeier R Meffert F Jakob

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


48 patients with painful bone marrow lesions were randomized to receive Vitamin D and calcium supplementation plus a single dose of intravenous Zoledronic acid (n=34) or placebo (n=14). The primary outcome of interest was the change in volume/size of the lesion. Secondary outcomes of interest included pain on a Visual Analog Scale (VAS), pain disability index (PDI), bone-specific quality of life q...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.